Opioid Free Pain Leverage the FDA-approved non-opioid topical therapy for neuropathic pain due to postherpetic neuralgia and diabetic peripheral neuropathy of the feet to differentiate in the US market. Focus outreach on pain management specialists, neurology, physical medicine and rehabilitation, endocrinology, and podiatry, emphasizing safety, efficacy, and opioid-sparing benefits to support payer value propositions.

Clinical Study Partnerships Active post-market observational studies with external collaborators demonstrate a strong appetite for real-world evidence. Use these programs to position clinical data as a differentiator for clinician education, payer discussions, and future indications exploration, while expanding site networks for broader patient access.

Patient Engagement Channels Direct patient engagement campaigns indicate a clear channel to raise awareness, aid earlier identification of neuropathic symptoms, and support patient recruitment for studies and adoption efforts, particularly among individuals with diabetic neuropathy and postherpetic neuralgia.

US Commercial Footprint Strong US commercial footprint backed by a global private parent enables rapid access to healthcare providers, payers, and distribution networks. There is opportunity to co-market or cross-sell within the Grünenthal ecosystem and to accelerate market penetration with shared marketing resources and regulatory know-how.

Ecosystem Leverage Solid financial backing and mid-market scale provide the ability to invest in market development, evidence generation, and clinician education programs, accelerating outreach to targeted specialties and payer conversations to improve adoption.